Studies (prospective, retrospective and case reports) of second trimester misoprostol termination (16 to 28 weeks) in women with a prior caesarean birth were eligible for inclusion. The primary outcome was incidence of uterine rupture. Other outcomes eligible for inclusion were maternal complications such as hysterectomy and blood transfusion.
Included studies were of vaginal, oral or sublingual misoprostol in doses that ranged from 200μg to 800μg administered at intervals of one to 12 hours. Where stated, gestational age ranged from 14 to 28 weeks. Most terminations were of live foetus.
The authors stated neither how the studies were selected for the review nor how many reviewers performed the study selection.